Myelodysplastic Syndrome (MDS) Drugs - Global Strategic Business Report

Global Myelodysplastic Syndrome (MDS) Drugs Market to Reach $4.1 Billion by 2030

The global market for Myelodysplastic Syndrome (MDS) Drugs estimated at US$1.9 Billion in the year 2022, is projected to reach a revised size of US$4.1 Billion by 2030, growing at a CAGR of 10.4% over the analysis period 2022-2030. Immunomodulatory Drugs, one of the segments analyzed in the report, is projected to record 10.8% CAGR and reach US$2.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Hypomethylating Agents segment is readjusted to a revised 5.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $510.7 Million, While China is Forecast to Grow at 16.7% CAGR

The Myelodysplastic Syndrome (MDS) Drugs market in the U.S. is estimated at US$510.7 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 16.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.5% and 8.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6% CAGR.

Select Competitors (Total 34 Featured) -

• Amgen
• BluePoint Laboratories
• Celgene Corporation
• Celgene Europe Limited
• Johnson & Johnson
• Lupin Ltd Corporation
• Otsuka America Pharmaceutical Inc.
• Reddy's Laboratories, Inc.
• Sandoz
• Shilpa Medicare Limited
• Sun Pharmaceutical Industries Inc.
• Takeda

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its 'bumpy' reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year